AU2013335678B9 - Therapeutic agent for amyotrophic lateral sclerosis - Google Patents

Therapeutic agent for amyotrophic lateral sclerosis Download PDF

Info

Publication number
AU2013335678B9
AU2013335678B9 AU2013335678A AU2013335678A AU2013335678B9 AU 2013335678 B9 AU2013335678 B9 AU 2013335678B9 AU 2013335678 A AU2013335678 A AU 2013335678A AU 2013335678 A AU2013335678 A AU 2013335678A AU 2013335678 B9 AU2013335678 B9 AU 2013335678B9
Authority
AU
Australia
Prior art keywords
amino acid
ghrelin
therapeutic agent
acid residue
lateral sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013335678A
Other languages
English (en)
Other versions
AU2013335678A1 (en
AU2013335678B2 (en
Inventor
Mayumi Furuya
Tsuyoshi Matsuo
Norihito Murayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2013335678A1 publication Critical patent/AU2013335678A1/en
Publication of AU2013335678B2 publication Critical patent/AU2013335678B2/en
Application granted granted Critical
Publication of AU2013335678B9 publication Critical patent/AU2013335678B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
AU2013335678A 2012-10-24 2013-10-23 Therapeutic agent for amyotrophic lateral sclerosis Active AU2013335678B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
JP2012-234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Publications (3)

Publication Number Publication Date
AU2013335678A1 AU2013335678A1 (en) 2015-05-21
AU2013335678B2 AU2013335678B2 (en) 2017-10-26
AU2013335678B9 true AU2013335678B9 (en) 2024-12-12

Family

ID=50544716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013335678A Active AU2013335678B9 (en) 2012-10-24 2013-10-23 Therapeutic agent for amyotrophic lateral sclerosis

Country Status (11)

Country Link
US (1) US20150265680A1 (enExample)
EP (1) EP2913063B1 (enExample)
JP (1) JP6262661B2 (enExample)
KR (3) KR102499918B1 (enExample)
CN (2) CN104853778A (enExample)
AU (1) AU2013335678B9 (enExample)
BR (1) BR112015009107A2 (enExample)
CA (1) CA2889499C (enExample)
IN (1) IN2015DN04172A (enExample)
RU (1) RU2655811C2 (enExample)
WO (1) WO2014065341A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791038A1 (ru) 2014-11-12 2017-11-30 Лирик Фармасьютикалз Инк. Лечение непереносимости энтерального питания
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
MA54383A (fr) * 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258250A1 (en) * 1999-12-28 2002-11-20 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CN1161333C (zh) 1998-08-20 2004-08-11 住友制药株式会社 作为生长激素释放剂的2-羟基吲哚衍生物
CA2380058C (en) * 1999-07-23 2011-08-09 Kenji Kangawa Novel peptides
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
ATE302181T1 (de) 2000-06-13 2005-09-15 Zentaris Gmbh Verbindungen zur stimulation der sekretion von wachstumshormonen
EP1493747B1 (en) 2002-04-11 2012-12-19 Daiichi Sankyo Company, Limited Process for producing modified peptide
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
EP1938814A4 (en) * 2005-10-18 2009-06-03 Ono Pharmaceutical Co PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
WO2009121759A2 (en) * 2008-04-03 2009-10-08 F. Hoffmann-La Roche Ag Use of pegylated igf-i variants for the treatment of neuromuscular disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258250A1 (en) * 1999-12-28 2002-11-20 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B. HOLST ET AL, "Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor", MOLECULAR PHARMACOLOGY, US, (20090101), vol. 75, no. 1, pages 44 - 59 *
DIANA GARCIA DEL BARCO ET AL: "Therapeutic Effect of the Combined Use of Growth Hormone Releasing Peptide-6 and Epidermal Growth Factor in an Axonopathy Model", NEUROTOXICITY RESEARCH, vol. 19, no. 1, 19 February 2010 , pages 195-209 *
LEE S ET AL., "Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation", KOREAN J PHYSIOL PHARMACOL, (201202), vol. 16, no. 1, pages 43 - 8 *

Also Published As

Publication number Publication date
EP2913063A4 (en) 2016-07-20
RU2015119472A (ru) 2016-12-20
US20150265680A1 (en) 2015-09-24
JPWO2014065341A1 (ja) 2016-09-08
CA2889499C (en) 2019-09-10
AU2013335678A1 (en) 2015-05-21
IN2015DN04172A (enExample) 2015-10-16
EP2913063A1 (en) 2015-09-02
CN104853778A (zh) 2015-08-19
WO2014065341A1 (ja) 2014-05-01
KR20200108494A (ko) 2020-09-18
BR112015009107A2 (pt) 2017-11-14
KR20150070180A (ko) 2015-06-24
CA2889499A1 (en) 2014-05-01
JP6262661B2 (ja) 2018-01-17
RU2655811C2 (ru) 2018-05-29
KR102499918B1 (ko) 2023-02-14
AU2013335678B2 (en) 2017-10-26
CN110354265A (zh) 2019-10-22
KR20220051418A (ko) 2022-04-26
HK1214152A1 (en) 2016-07-22
EP2913063B1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
JP6552117B2 (ja) 敗血症の予防治療剤
JP5956664B2 (ja) 脂肪異栄養症の処置
EP0309100B1 (en) Use of amylin or CGRP for the treatment of diabetes mellitus
US20220111010A1 (en) Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus
CN115124602B (zh) Gip和glp-1的双受体激动剂、药物组合物及用途
AU2013335678B2 (en) Therapeutic agent for amyotrophic lateral sclerosis
CN105518021A (zh) 药物组合物
KR20200038408A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
TW201321403A (zh) 藉由Ｋｖ１．３鉀通道之藥物標靶治療肥胖及肥胖相關疾病
WO2024027553A1 (zh) 一种双功能融合蛋白及其用途
HK1214152B (en) Therapeutic agent for use in treating amyotrophic lateral sclerosis
EP2790703B1 (en) Samidorphan (alks 33) in combination with opioid agonists
WO2023245543A1 (en) Uses of fgf21 fusion proteins
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
EP4017870B1 (en) Compositions and methods for treating and preventing autoimmune induced cardiac long qt syndrome
US20250161255A1 (en) New therapy and prevention for suppressing aging-related disorders including sarcopenia
US20080125360A1 (en) Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
JP2007538017A (ja) 胃腸疾患の治療のためのｐｐｙ含有組成物
US11028141B2 (en) Therapeutic for the prevention and/or treatment of weight gain and/or diabetes
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
WO2026056985A1 (zh) 抑郁症的治疗方法和药物组合物
CN101128213A (zh) 胰腺β细胞再生的促进剂以及在胰腺β细胞中生产胰岛素的促进剂
HK1197180B (en) Samidorphan (alks 33) in combination with opioid agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
ROP Revocation of patent

Effective date: 20241122

SREP Specification republished